TOVX
Price:
$4.37
Market Cap:
$4.39M
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops...[Read more]
Industry
Biotechnology
IPO Date
2006-12-18
Stock Exchange
NYSE
Ticker
TOVX
According to Theriva Biologics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.14. This represents a change of -63.65% compared to the average of -0.39 of the last 4 quarters.
The mean historical PE Ratio of Theriva Biologics, Inc. over the last ten years is -49.09. The current -0.14 PE Ratio has changed -71.48% with respect to the historical average. Over the past ten years (40 quarters), TOVX's PE Ratio was at its highest in in the December 2017 quarter at 147.90. The PE Ratio was at its lowest in in the December 2016 quarter at -208.25.
Average
-49.09
Median
-38.36
Minimum
-114.17
Maximum
-0.35
Discovering the peaks and valleys of Theriva Biologics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 221.41%
Maximum Annual PE Ratio = -0.35
Minimum Annual Increase = -99.39%
Minimum Annual PE Ratio = -114.17
Year | PE Ratio | Change |
---|---|---|
2023 | -0.38 | 6.59% |
2022 | -0.35 | -99.39% |
2021 | -58.51 | 221.41% |
2020 | -18.21 | 31.26% |
2019 | -13.87 | 112.48% |
2018 | -6.53 | -93.92% |
2017 | -107.44 | 63.07% |
2016 | -65.89 | -37.57% |
2015 | -105.53 | -7.56% |
2014 | -114.17 | -19.42% |
The current PE Ratio of Theriva Biologics, Inc. (TOVX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-19.75
5-year avg
-18.26
10-year avg
-49.09
Theriva Biologics, Inc.’s PE Ratio is greater than Lumos Pharma, Inc. (-0.86), less than Diffusion Pharmaceuticals Inc. (-0.00), greater than Avalo Therapeutics, Inc. (-0.22), greater than Catalyst Biosciences, Inc. (-0.44), less than Panbela Therapeutics, Inc. (-0.06), less than Virpax Pharmaceuticals, Inc. (-0.10), less than Revelation Biosciences, Inc. (-0.09), less than Biodexa Pharmaceuticals Plc (-0.05), greater than Praxis Precision Medicines, Inc. (-8.22), greater than First Wave BioPharma, Inc. (-0.85), less than Salarius Pharmaceuticals, Inc. (-0.14), greater than SAB Biotherapeutics, Inc. (-0.65), greater than Vaccinex, Inc. (-0.58), greater than GeoVax Labs, Inc. (-0.32), less than Kintara Therapeutics, Inc. (-0.08), greater than Fresh Tracks Therapeutics, Inc. (-0.78), greater than Lisata Therapeutics, Inc. (-1.22), greater than Marker Therapeutics, Inc. (-2.58), greater than Exicure, Inc. (-1.84), greater than Protagenic Therapeutics, Inc. (-0.52), greater than PMV Pharmaceuticals, Inc. (-1.58),
Company | PE Ratio | Market cap |
---|---|---|
-0.86 | $30.87M | |
-0.00 | $8.98M | |
-0.22 | $7.82M | |
-0.44 | $19.42M | |
-0.06 | $1.75M | |
-0.10 | $4.06M | |
-0.09 | $1.43M | |
-0.05 | $105.64K | |
-8.22 | $959.24M | |
-0.85 | $5.99M | |
-0.14 | $2.15M | |
-0.65 | $26.21M | |
-0.58 | $9.73M | |
-0.32 | $28.68M | |
-0.08 | $9.63M | |
-0.78 | $4.42M | |
-1.22 | $25.79M | |
-2.58 | $26.59M | |
-1.84 | $3.01M | |
-0.52 | $3.37M | |
-1.58 | $77.28M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Theriva Biologics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Theriva Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Theriva Biologics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Theriva Biologics, Inc. (TOVX)?
What is the highest PE Ratio for Theriva Biologics, Inc. (TOVX)?
What is the 3-year average PE Ratio for Theriva Biologics, Inc. (TOVX)?
What is the 5-year average PE Ratio for Theriva Biologics, Inc. (TOVX)?
How does the current PE Ratio for Theriva Biologics, Inc. (TOVX) compare to its historical average?